LH (Labcorp Holdings) Cash per Share : $18.13 (As of Sep. 2024)

View and export this data going back to 1991. Start your Free Trial

What is Labcorp Holdings Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Labcorp Holdings's Cash per Share for the quarter that ended in Sep. 2024 was $18.13.

Labcorp Holdings Cash per Share Historical Data

The historical data trend for Labcorp Holdings's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Labcorp Holdings Cash per Share Chart

Labcorp Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash per Share

Get a 7-Day Free Trial

3.47

13.55

15.82

3.64

6.40

Labcorp Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash per Share	Get a 7-Day Free Trial															8.57	6.40	1.18	3.16	18.13

Labcorp Holdings Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Labcorp Holdings's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	536.8	/	84
	=	6.40

Labcorp Holdings's Cash per Share for the quarter that ended in Sep. 2024 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	1517.3	/	84
	=	18.13

Labcorp Holdings (NYSE:LH) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Labcorp Holdings Cash per Share Related Terms

Thank you for viewing the detailed overview of Labcorp Holdings's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Labcorp Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Labcorp Holdings Inc (NYSE:LH) » Definitions » Cash per Share

Comparable Companies

Traded in Other Exchanges

LH:Mexico 0JSY:UK N6B:Germany

Address

358 South Main Street, Burlington, NC, USA, 27215

Website

https://www.labcorp.com

Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.

Executives

Dwight Gary Gilliland	director	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Glenn A Eisenberg	officer: Chief Financial Officer, EVP	P O BOX 1017, CHARLOTTE NC 28201-1017
Amy B. Summy	officer: EVP, Chief Marketing Officer	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Van Der Vaart Sandra D	officer: SVP, Global General Counsel	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Adam H Schechter	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Kerrii B Anderson	director	WENDY'S INTERNATIONAL, INC, 4288 WEST DUBLIN-GRANVILLE RD., DUBLIN OH 43017
Lance Berberian	officer: SVP, Chief Information Officer
Peter J Wilkinson	officer: SVP, Chief Accounting Officer	C/O PHARMACEUTICAL PRODUCT DEVELOPMENT, 929 NORTH FRONT STREET, WILMINGTON NC 28401
Mark S Schroeder	officer: EVP, President-Diagnostics Lab	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Paul Rothman	director	6 MEADOW ROAD, BALTIMORE MD 21212
Paul R Kirchgraber	officer: CEO, Covance Drug Development	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Megan D. Bailey	officer: EVP, Chief Strategy Officer	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Jonathan P. Divincenzo	officer: EVP, Pres, Central Labs & Intl	940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451
Anita Z Graham	officer: EVP, CHRO	C/O THE ADT CORPORATION, 1501 YAMATO ROAD, BOCA RATON FL 33431
Thomas Pike	officer: Pres & CEO Clinical Business	C/O ACCENTURE, 161 N. CLARK STREET, 23RD FLOOR, CHICAGO IL 60601